Agappe Diagnostics is in early talks with global private equity firms to sell a 25% stake, valuing the Kochi-based company at up to ₹3,200 crore. The deal aims to raise primary capital for expansion while allowing existing investors to exit. This move underscores growing investor interest in India’s in-vitro diagnostics sector, which is seeing higher demand for local manufacturing and testing services.
Agappe Diagnostics, a Kochi-based leader in the in-vitro diagnostics (IVD) space, is exploring a significant stake sale to attract global private equity interest. Reports indicate that major global investment firms, including Warburg Pincus, TA Associates, Bain Capital, and CVC Capital, are in preliminary discussions to acquire approximately 25% of the company. The proposed deal is expected to range between ₹700 crore and ₹750 crore, placing the company’s total valuation in the ₹3,000 to ₹3,200 crore bracket.
The proposed transaction is structured to benefit both the company and its current shareholders. A portion of the deal will involve a secondary sale, allowing existing investors to monetize their holdings, while a primary capital infusion will provide the company with fresh funds. Such funding is typically used to enhance manufacturing capabilities or expand the company's product portfolio. Financial advisory firm Alvarez & Marsal is reportedly assisting the promoters with this process.
Founded in 1994, Agappe has built a business model centered on the development and manufacturing of diagnostic reagents and equipment. The company maintains a global footprint, supplying laboratories in more than 90 countries. Its core portfolio includes biochemistry analyzers like the Mispa Chem DX and hematology systems such as the Mispa Hx35. The company’s international operations are supported by its subsidiary, Agappe Diagnostics Switzerland GmbH, and it also acts as an exclusive distributor in India for international brands including Mindray and i-SENS.
From a financial perspective, the company’s growth outlook appears to be a key driver for investor interest. In fiscal year 2025, Agappe recorded revenue of $61 million with a profit after tax of $3.7 million. Looking ahead, the company is targeting revenue of approximately ₹650 crore by fiscal year 2027, with a projected EBITDA between ₹100 crore and ₹120 crore. This growth plan coincides with a broader shift in the Indian healthcare sector toward self-reliance in medical device manufacturing, supported by favorable government policies.
While the company holds a significant position in the domestic market, it operates in a sector characterized by high competition. It competes against large multinational corporations such as Roche and Siemens Healthcare, which have substantial research and distribution resources. Consequently, the ability of Agappe to maintain its profit margins while scaling its operations will be a critical monitorable for investors. Future updates regarding the final deal structure, the identity of the incoming investor, and the specific use of the new capital will determine the long-term impact on the company’s balance sheet and operational efficiency.